Trials Sponsors Conditions Drugs Pricing

Conditions

Central Serous Chorioretinopathy Juxtafoveal Telangiecasia Polypoidal Choroidal Vasculopathy Retinal Arterial Macroaneurysm Retinal Artery Occlusions

Keywords

RetinaOptical coherence tomographyImaging

Outcome Measures

Primary Outcomes (1)

Total Retinal and Choroidal Blood Flow
Determination whether disease affecting the retina and/or choroid shows a change in blood flow that differs from healthy eyes. Total retinal/choroidal blood flow will be measured in uL/min.
One year

Study Arms (1)

Rare Chorioretinal Disease

Up to 150 patients diagnosed with a rare retinal or choroidal disease will be considered and evaluated for enrollment in this study.

Eligibility Criteria

Age7 Years - 100 Years

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Individuals 18 years of age and older presenting to the Retina Service within the Department of Ophthalmology at the Casey Eye Institute of Oregon Health \& Science University with signs and symptoms of rare choroidal or retinal diseases will be evaluated for enrollment into this study.

You may not qualify if:

Inability to give informed consent.

Sponsors & Collaborators

Oregon Health and Science University
Otherlead

Study Sites (1)

Casey Eye Institute, Oregon Health & Science University

Portland, Oregon, 97239-3098, United States

RECRUITING

Kevin LathropCONTACT503-494-8024 lathropk@ohsu.edu

Denny Romfh, ODCONTACT503-494-4351 romfhd@ohsu.edu

John Campbell, MD, MPHSUB INVESTIGATOR

Andreas Lauer, MDSUB INVESTIGATOR

Christina Flaxel, MDSUB INVESTIGATOR

Michael Klein, MD

MeSH Terms

Conditions

Retinal Artery OcclusionPolypoidal Choroidal VasculopathyRetinal Arterial MacroaneurysmCentral Serous Chorioretinopathy

Condition Hierarchy (Ancestors)

Retinal DiseasesEye DiseasesArterial Occlusive DiseasesVascular DiseasesCardiovascular DiseasesChoroidal NeovascularizationChoroid DiseasesUveal DiseasesNeovascularization, PathologicMetaplasiaPathologic Processes

Study Officials

Thomas Hwang, MD
Oregon Health & Science Univeristy
PRINCIPAL INVESTIGATOR

Central Study Contacts

Kevin Lathrop

CONTACT

503-494-8024 lathropk@ohsu.edu

Denny Romfh, OD

CONTACT

503-494-4351

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Thomas Hwang, MD, Professor of Ophthalmology, Retina & Vitreous Diseases Division

Study Record Dates

First Submitted

May 15, 2014

First Posted

May 19, 2014

Study Start

May 2014

Actual (reported)

Primary Completion

December 2025

Estimated (date passed)

OCT in Rare Chorioretinal Diseases

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Rare Chorioretinal Disease

Eligibility Criteria

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Rare Chorioretinal Disease

Eligibility Criteria

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

Source record

Locations